Merck Serono, a division of Merck KGaA,Darmstadt, Germany, announced that the two-year Phase III REFLEX 1 study met its primary endpoint by demonstrating that Rebif® (interferon beta-1a) significantly delayed conversion to multiple sclerosis (MS) diagnosed according to the McDonald criteria 2 in patients with a first clinical event suggestive of the disease.
The international REFLEX study with 517 patients was conducted with the serum-free formulation of Rebif® 3, which was first introduced in 2007 and is now available in all European uni0n countries, Australia, Canada and Switzerland, as well as a number of countries in Asia, Latin America, Africa and the Middle East. The serum-free formulation of Rebif® is currently not available in the United States....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1765